Major Pharmaceutical Group
We acted for the parent company in this solvent liquidation of its subsidiary companies.
Our principal role was to reorganise and simplify this group’s corporate structure.
Specifically we had to deal with tax clearance and issues associated with the distribution of assets in excess of $600M to shareholders in the group.
The case was further complicated by managing trade mark issues including assignments in numerous countries.
This was highly successful and all distributions were effected.